1.Comparison of the Effect of Imipenem and Cilastatin Sodium and Meropenem in the Treatment of Acute Leukemia Granulocytopenic Phase Combined with Severe Lung Infection
Shanshan CHEN ; Min WANG ; Demin TAN ; Shuimiao CAI
China Pharmacy 2017;28(26):3684-3687
OBJECTIVE:To compare the clinical efficacy and safety of imipenem and cislastatin sodium and meropenem in the treatment of acute leukemia granulocytopenic phase combined with severe lung infection. METHODS:A total of 64 patients with acute leukemia granulocytopenic phase combined with severe lung infection were selected from our hospital during Jul. 2015-Jul. 2016 as study objects. They were divided into trial group(odd number)and control group(even number)according to admis-sion order,with 32 cases in each group. Control group was given Meropenem for injection 1 g+0.9% Sodium chloride injection 100 mL,ivgtt(about 30 min),q8 h. Trial group was given Imipenem and cislastatin sodium for injection 1 g+0.9% Sodium chlo-ride injection 100 mL,ivgtt(about 30 min),q12 h. Both groups were treated for 14 d. Clinical efficacies as well as blood gas pa-rameters [p(O2),p(CO2),SaO2] and pathogenic clearance were observed in 2 groups,and the occurrence of ADR was recorded. RESULTS:The total response rate of trial group(78.13%)was significantly higher than that of control group(71.88%),with sta-tistical significance (P<0.05). Before treatment,there was no statistical significance in blood gas parameters or the number of detected pathogenic strains between 2 groups (P>0.05). After treatment,the levels of p(O2) and SaO2 in 2 groups were in-creased significantly,while the level of p(CO2) was decreased significantly;there was statistical significance compared to be-fore treatment(P>0.05). There were 27 cases of pathogenic clearance in trial group(clearance rate of 84.38%),which was sig-nificantly more than control group (26 cases,clearance rate of 81.25%),without statistical significance (P>0.05). The inci-dence of ADR in trial group(9.38%)was significantly lower than control group(15.63%),without statistical significance(P>0.05). CONCLUSIONS:Imipenem and cislastatin sodium and meropenem show good clinical efficacy for acute leukemia granu-locytopenic phase combined with severe lung infection,blood gas parameters improvement and pathogenic clearance effect,both of them have good safety.